Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Shares Bought by Barclays PLC

Barclays PLC raised its holdings in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 152.2% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 75,052 shares of the specialty pharmaceutical company’s stock after purchasing an additional 45,291 shares during the period. Barclays PLC owned 0.23% of Collegium Pharmaceutical worth $2,899,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the business. Virtus Fund Advisers LLC acquired a new position in Collegium Pharmaceutical during the 3rd quarter valued at about $72,000. Wellington Management Group LLP grew its stake in shares of Collegium Pharmaceutical by 17.2% during the third quarter. Wellington Management Group LLP now owns 114,640 shares of the specialty pharmaceutical company’s stock worth $4,430,000 after acquiring an additional 16,784 shares during the last quarter. Janus Henderson Group PLC increased its holdings in shares of Collegium Pharmaceutical by 399.4% during the third quarter. Janus Henderson Group PLC now owns 69,485 shares of the specialty pharmaceutical company’s stock valued at $2,686,000 after acquiring an additional 55,572 shares in the last quarter. ClearAlpha Technologies LP purchased a new position in shares of Collegium Pharmaceutical in the 3rd quarter valued at approximately $266,000. Finally, Verition Fund Management LLC boosted its stake in Collegium Pharmaceutical by 35.1% in the 3rd quarter. Verition Fund Management LLC now owns 14,042 shares of the specialty pharmaceutical company’s stock worth $543,000 after purchasing an additional 3,652 shares in the last quarter.

Analyst Ratings Changes

COLL has been the topic of a number of recent analyst reports. Piper Sandler restated a “neutral” rating and set a $37.00 price target on shares of Collegium Pharmaceutical in a research note on Friday, October 11th. HC Wainwright upped their target price on Collegium Pharmaceutical from $47.00 to $50.00 and gave the company a “buy” rating in a research report on Thursday, September 5th. Finally, StockNews.com cut Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, October 23rd. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $42.60.

Collegium Pharmaceutical Trading Down 0.3 %

NASDAQ COLL opened at $29.06 on Wednesday. The company has a fifty day moving average of $32.30 and a 200 day moving average of $34.30. The company has a market capitalization of $937.19 million, a PE ratio of 12.53 and a beta of 0.80. The company has a debt-to-equity ratio of 3.43, a current ratio of 0.97 and a quick ratio of 0.88. Collegium Pharmaceutical, Inc. has a 1 year low of $28.75 and a 1 year high of $42.29.

Collegium Pharmaceutical Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.